MedicalResearch.com Interview with: [caption id="attachment_69277" align="alignleft" width="170"] Dr. Troum[/caption] Orrin M. Troum, MD Orrin M. Troum, MD, is a Clinical Professor of Medicine and Voluntary Faculty Member of the Division of Rheumatology Keck School of Medicine- UCLA Director, Clinical Rheumatology Research Providence St John's Hospital Santa Monica, California MedicalResearch.com: What is the background for this study? Who is more likely to develop uncontrolled gout? Response: The Phase 4, open-label FORWARD trial was designed to evaluate the safety and efficacy of less frequent, monthly dosing of KRYSTEXXA^® (pegloticase) co-administered with methotrexate (MTX) in patients with uncontrolled gout. KRYSTEXXA remains the only FDA-approved therapy for this challenging condition, but with continued research like the FORWARD trial, we can further improve and evolve the treatment landscape for patients. This study reflects a broader effort to optimize gout care with approaches that are not only effective but also more sustainable in real-world settings. Uncontrolled gout happens when gout is not properly treated and uric acid levels continue to rise, which can have a damaging impact on the body beyond the pain of regular flares. Those experiencing uncontrolled gout continue to have signs and symptoms of gout despite taking oral urate-lowering medicines.